**National Cancer Institute (NCI) -- Patient-Derived Models Repository (PDMR) Program**

**MATERIAL TRANSFER AGREEMENT**

## For International Distribution

## Summary Page (“Coversheet”)

Name of Recipient: Click or tap here to enter text.

Name of Investigator: Click or tap here to enter text.

Mailing Address: Click or tap here to enter text.

Click or tap here to enter text.

Click or tap here to enter text.

Country: Click or tap here to enter text.

Telephone: Click or tap here to enter text.

Fax: Click or tap here to enter text.

**Term of Agreement**: This Agreement will continue in perpetuity until cancelled in writing by Recipient for any reason or by Provider for breach of this Agreement.

The entire text of the Terms of Agreement can be found at <https://pdmr.cancer.gov/content/docs/Material_Transfer_Terms_of_Agreement_ver-2025-05-01.pdf> and are herein incorporated by reference.

A new Article 12 is added to the Terms of Agreement as follows:

12. This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed and construed in accordance with the law of Recipient’s country if a claim is brought against Recipient, and with the law of the United States if a claim is brought against NCI.

The Annual Report (identified in Article 9) containing all data generated using these materials is to be returned to the NCI Patient-Derived Models Repository. An Annual Report is due on the first and each subsequent anniversary of the Effective Date for the first five (5) years following the Effective Date, as defined below. If the Agreement is terminated for any reason, a final Annual Report will be due within 90 days of termination.

For your convenience, an Annual Report template for data entry may be found at <https://pdmr.cancer.gov/content/docs/NCI_PDMR_Annual_Report.pdf> or requested from the Repository at [NCI\_PDM\_Repository@mail.nih.gov](mailto:NCI_PDM_Repository@mail.nih.gov).

The report may be submitted by email to: [NCI\_PDM\_Repository@mail.nih.gov](mailto:NCI_PDM_Repository@mail.nih.gov). Whole exome and genome files and RNASeq files should be submitted as zipped FASTQ files or an FTP of Globus drop can be established; please contact the NCI-PDMR for details.

Send MTA paperwork to: [NCI\_PDM\_Repository@mail.nih.gov](mailto:NCI_PDM_Repository@mail.nih.gov)

Email: Click or tap here to enter text.

## Signature Page

The RECIPIENT and PROVIDER have entered into this Agreement effective as of the Recipient’s signature date below (“Effective Date”) and agree to be bound by the Terms of Agreement, found here: <https://pdmr.cancer.gov/content/docs/Material_Transfer_Terms_of_Agreement_ver-2025-05-01.pdf>, as amended by the terms on the Coversheet, and each of the undersigned represents and confirms that they are fully authorized to bind their identified entity to its terms:

**RECIPIENT INFORMATION**

|  |  |
| --- | --- |
| RECIPIENT: | Click or tap here to enter text. |
| Address: | Click or tap here to enter text. |
| Name of Authorized Official: | Click or tap here to enter text. |
| Title of Authorized Official: | Click or tap here to enter text. |
| Signature of Authorized Official: |  |
| Date |  |

Address for Notices Regarding the Materials:

Cindy R. Timme, Ph.D.

Frederick National Laboratory for Cancer

1050 Boyles St. Bldg. 1066, Rm. 126

Frederick, MD 21702

Phone: 301-846-1327

Address for Legal Notices:

Technology Transfer Center.

National Cancer Institute

9609 Medical Center Drive, Rm 1E-530

Bethesda, MD, 20892-9702

Phone: 240-276-5530

**Appendix 1: PDX Materials**

**Patient-Derived Xenograft Materials (format: 123456-123-X). Cannot request specific fragments. Distribution lots can be found listed in the PDMR Database at the following link:** <https://pdmdb.cancer.gov/pls/apex/f?p=101:41>

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| # | Distribution Lot Name | Cryovial for PDX Generation | PDX DNA Vial | PDX RNA Vial | PDX Flash-Frozen Vial |
| 1 |  |  |  |  |  |
| 2 |  |  |  |  |  |
| 3 |  |  |  |  |  |
| 4 |  |  |  |  |  |
| 5 |  |  |  |  |  |
| 6 |  |  |  |  |  |
| 7 |  |  |  |  |  |
| 8 |  |  |  |  |  |
| 9 |  |  |  |  |  |
| 10 |  |  |  |  |  |
| 11 |  |  |  |  |  |
| 12 |  |  |  |  |  |
| 13 |  |  |  |  |  |
| 14 |  |  |  |  |  |
| 15 |  |  |  |  |  |
| 16 |  |  |  |  |  |
| 17 |  |  |  |  |  |
| 18 |  |  |  |  |  |
| 19 |  |  |  |  |  |
| 20 |  |  |  |  |  |

**Appendix 2: In Vitro Materials**

**Patient-Derived Tumor Culture (PDC), Cancer-Associated Fibroblast (CAF), and Organoid (PDOrg) Material (format: 123456-123-X-PDC, 123456-123-X-CAF, 123456-123-X-organoid). Distribution lots can be found listed in the PDMR Database on the in vitro culture tab at the following link:** <https://pdmdb.cancer.gov/pls/apex/f?p=101:43>

|  |  |  |
| --- | --- | --- |
| # | Distribution Lot Name | Cryovial for  In Vitro Culture Material |
| 1 |  |  |
| 2 |  |  |
| 3 |  |  |
| 4 |  |  |
| 5 |  |  |
| 6 |  |  |
| 7 |  |  |
| 8 |  |  |
| 9 |  |  |
| 10 |  |  |
| 11 |  |  |
| 12 |  |  |
| 13 |  |  |
| 14 |  |  |
| 15 |  |  |
| 16 |  |  |
| 17 |  |  |
| 18 |  |  |
| 19 |  |  |
| 20 |  |  |